Jun 2026 (Q2 FY26) — Aug 13, 2026
Tenon Medical Q2 FY26 — Record Revenue and Gross Margin Expansion Driven by Procedure Growth
Read the full callTenon Medical (TNON) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Tenon Medical earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.3 | +126.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -262.2 | +244.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -4.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.7 −7.22% · −$0.21
Performance −93.7% 1Y
1Y: $43.05 on 15 Oct 2025 → $2.7. High $45.15 (12 Nov 2025), low $2.44 (9 Sept 2026).
- Previous close
- $2.91
- 52-week range
- $2.44 – $45.15
- One year
- −93.83%
Overview
- Symbol
- TNON
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Tenon Medical earnings calls (TNON)
Financials
What the filings say
Net profit, year on year: −46% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating profit | -3 | -3 | -4 | -3 | -3 | -3 | -3 | -3 |
| Operating margin | −362.5% | −412.1% | −506.5% | −506.6% | −289.2% | −193.5% | −237.8% | −262.2% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -1 |
| Interest | — | 0 | — | — | — | — | 0 | 1 |
| Net profit | -3 | -3 | -4 | -3 | -3 | -3 | -3 | -4 |
| EPS ($ per share) | -3.63 | — | -1.01 | -12.76 | -0.40 | — | -0.31 | -12.35 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 |
| Reserves | -21 | -39 | -55 | -69 | -81 |
| Total liabilities | 16 | 5 | 6 | 4 | 6 |
| Fixed assets | 0 | 1 | 1 | 1 | 1 |
| Investments | 4 | 6 | — | — | — |
| Total assets | 9 | 11 | 6 | 10 | 11 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash from operations | -4 | -12 | -12 | -10 | -11 |
| Cash from investing | -5 | -3 | 6 | -0 | -1 |
| Cash from financing | 11 | 14 | 6 | 14 | 9 |
| Net cash flow | 3 | -1 | 0 | 4 | -3 |
| Capital expenditure | -0 | -1 | -0 | -0 | -0 |
| Free cash flow | -4 | -13 | -13 | -10 | -11 |
Insider filings
51 filings between Nov 14, 2025 and Sep 10, 2026.
Open market
decisions to buy or sellPurchases
$500.2K
12 purchases by 4 insiders
Sales
$605.7K
9 sales by 1 insider
Some filings report no price, so the dollar figures above are a floor, not a total.
Compensation
not trading decisions- 2
- Award — granted as compensation
- 19
- Option exercise — converted options into shares
- 9
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| HRT FINANCIAL LP | $500.2K | $605.7K | Sep 10, 2026 |
| FOSTER STEVEN M | $0 | — | Nov 14, 2025 |
| Geist Wyatt D. | $0 | — | Nov 14, 2025 |
| Grawey Nathaniel A. | $0 | — | Nov 14, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | HRT FINANCIAL LP 10% owner | Sale | 65,582 | $364.6K |
| Sep 10, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 31,227 | $91.2K |
| Sep 10, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 28,267 | $113.6K |
| Sep 10, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 8,431 | $41.5K |
| Sep 9, 2026 | HRT FINANCIAL LP 10% owner | Sale | 50,395 | $131.5K |
| Sep 9, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 39,508 | $134.3K |
| Sep 9, 2026 | HRT FINANCIAL LP 10% owner | Sale | 9,948 | $42.5K |
| Sep 9, 2026 | Williamson Kevin Chief Financial Officer | Tax withheld | 11 | $38 |
| Sep 8, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 707 | $2.4K |
| Sep 8, 2026 | Williamson Kevin Chief Financial Officer | Option exercise | 30 | $0 |
| Sep 4, 2026 | HRT FINANCIAL LP 10% owner | Sale | 1,506 | $5.6K |
| Sep 3, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 1,658 | $6.6K |
| Sep 2, 2026 | HRT FINANCIAL LP 10% owner | Sale | 450 | $2.0K |
| Sep 1, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 1,790 | $8.2K |
| Aug 31, 2026 | HRT FINANCIAL LP 10% owner | Sale | 1,276 | $5.9K |
| Aug 28, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 5,981 | $38.0K |
| Aug 28, 2026 | HRT FINANCIAL LP 10% owner | Purchase | 12,376 | $64.5K |
| Aug 28, 2026 | HRT FINANCIAL LP 10% owner | Sale | 2,091 | $16.5K |
| Aug 28, 2026 | HRT FINANCIAL LP 10% owner | Sale | 4,932 | $34.9K |
| Aug 27, 2026 | HRT FINANCIAL LP 10% owner | Sale | 419 | $2.1K |
| Aug 3, 2026 | GINN RICHARD Chief Technology Officer | Tax withheld | 44,809 | $8.9K |
| Aug 3, 2026 | FOSTER STEVEN M CEO and President | Tax withheld | 41,788 | $8.3K |
| Aug 3, 2026 | Williamson Kevin Chief Financial Officer | Tax withheld | 12,978 | $2.6K |
| Jul 31, 2026 | Williamson Kevin Chief Financial Officer | Option exercise | 58,987 | $0 |
| Jul 31, 2026 | Ferrari Richard Director | Option exercise | 64,479 | $0 |
| Jul 31, 2026 | Jacques Kristine M Director | Option exercise | 10,147 | $0 |
| Jul 31, 2026 | HOWARD IVAN Director | Option exercise | 10,732 | $0 |
| Jul 31, 2026 | WEIGLE ROBERT K Director | Option exercise | 10,732 | $0 |
| Jul 31, 2026 | Hochschuler Stephen Director | Option exercise | 10,732 | $0 |
| Jul 31, 2026 | FOSTER STEVEN M CEO and President | Option exercise | 140,936 | $0 |
| Jul 31, 2026 | GINN RICHARD Chief Technology Officer | Option exercise | 126,577 | $0 |
| May 1, 2026 | Geist Wyatt D. Chief Innovation Officer | Award | 136,401 | $0 |
| May 1, 2026 | Grawey Nathaniel A. Chief Commercial Officer | Award | 68,201 | $0 |
| Mar 3, 2026 | Williamson Kevin Chief Financial Officer | Option exercise | 1,041 | $0 |
| Jan 5, 2026 | Hochschuler Stephen Director | Tax withheld | 3,327 | $3.1K |
| Jan 5, 2026 | WEIGLE ROBERT K Director | Tax withheld | 3,413 | $3.2K |
| Jan 5, 2026 | GINN RICHARD Chief Technology Officer | Tax withheld | 47,426 | $44.1K |
| Jan 5, 2026 | Williamson Kevin Chief Financial Officer | Tax withheld | 18,518 | $17.2K |
| Jan 5, 2026 | HOWARD IVAN Director | Tax withheld | 3,327 | $3.1K |
| Jan 1, 2026 | Williamson Kevin Chief Financial Officer | Option exercise | 58,987 | $0 |
| Jan 1, 2026 | Ferrari Richard Director | Option exercise | 64,478 | $0 |
| Jan 1, 2026 | Jacques Kristine M Director | Option exercise | 583 | $0 |
| Jan 1, 2026 | Jacques Kristine M Director | Option exercise | 10,146 | $0 |
| Jan 1, 2026 | FOSTER STEVEN M CEO and President | Option exercise | 140,936 | $0 |
| Jan 1, 2026 | Hochschuler Stephen Director | Option exercise | 10,732 | $0 |
| Jan 1, 2026 | WEIGLE ROBERT K Director | Option exercise | 10,732 | $0 |
| Jan 1, 2026 | HOWARD IVAN Director | Option exercise | 10,732 | $0 |
| Jan 1, 2026 | GINN RICHARD Chief Technology Officer | Option exercise | 126,577 | $0 |
| Nov 14, 2025 | Grawey Nathaniel A. Chief Commercial Officer | Purchase | 101,167 | — |
| Nov 14, 2025 | Geist Wyatt D. Chief Innovation Officer | Purchase | 19,455 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Tenon Medical, Inc.
Free account. Everything above stays public.
Write why you follow Tenon Medical, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading